Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$7.72 USD
-0.58 (-6.99%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.70 -0.02 (-0.26%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
XERS 7.72 -0.58(-6.99%)
Will XERS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XERS
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Other News for XERS
Is XERS showing upside potential? Crossed Above 20 Day Moving Average shows up after surging 8.21%
Stochastic Buy Signal appears for XERS after 2.68% move
Xeris Pharmaceuticals (XERS) Receives a Buy from H.C. Wainwright
Bollinger Band Squeeze appears for XERS after 1.49% move
XERS forms Stochastic Reached Oversold on September 15